Percorrer por autor "Akhtar, Md Sayeed"
A mostrar 1 - 2 de 2
Resultados por página
Opções de ordenação
- Enhancing therapy with nano-based delivery systems: exploring the bioactive properties and effects of apigeninPublication . Kumar, Girish; Jain, Pushpika; Virmani, Tarun; Sharma, Ashwani; Akhtar, Md Sayeed; Aldosari, Saad A; Khan, Mohd Faiyaz; Duarte, Sofia O D; Fonte, PedroApigenin, a poten t na tural flav onoid , has emerged as a key therapeutic agent due to its multifac et ed medicinal properties in combating various diseases. How ev er, apigenin’s clinical utility is greatly limited by its poor w a ter solubility, low bioav ailabilit y and stabilit y issues. To address these challenges, this review paper explores the innov a tive field of nanotechnology-based delivery sy st ems, which have shown significant promise in improving the delivery and effectiveness of apigenin. This paper also explores the synerg istic pot ential of c o-delivering apigenin with conventional therapeutic agents. Despite the advantageous properties of these nanoformulations, critical challenges such as scalable pr oduction, r egulatory appr ovals and compr ehensiv e long-term safety assessments remain key hurdles in their clinical adoption which must be addressed for commercialization of apigenin-based formulations.
- Transforming cancer treatment: the potential of nanonutraceuticalsPublication . Kumar, Girish; Virmani, Tarun; Chhabra, Vaishnavi; Virmani, Reshu; Pathak, Kamla; Akhtar, Md Sayeed; Asim, Mulazim Hussain; Arshad, Shumaila; Siddique, Farzana; Fonte, PedroChemotherapy in the management of cancer is constrained by limitations like off-target effects, poor bioavailability, and dose-dependent toxicity. Nutraceuticals have been explored as an innovative strategy to overcome chemotherapy drawbacks. However, the clinical utility of nutraceuticals is restricted due to their complex structures, less water solubility, reduced stability, decreased bioavailability and more obstacles in the gastrointestinal tract. Nanonutraceuticals are nanosized nutraceutical particles having enhanced solubility, improved bioavailability, stability, and targeted delivery to specific cells. Nutraceuticals can be co-delivered with other chemotherapeutic drugs in nanocarriers to elicit synergistic effects. The targeting of nutraceuticals against cancer cells can be enabled by coupling ligands with the nanocarriers, which direct to the overexpressed receptors found at the surface of the cancer cells. Transitioning a nanonutraceutical from pre-clinical research to clinical trials is a pivotal step. This focus on advancing their application holds great potential for impacting clinical research and improving the treatment landscape for cancer patients. This review focuses on the role of nutraceuticals for cancer treatment, various nanocarriers for the efficient delivery of nutraceuticals along with co-administration of nutraceuticals with chemotherapeutic drugs using nanocarriers. Also, emphasize the targeting of ligands coupled nanocarriers to the cancer cells along with patents and clinical trials for nanonutraceuticals.